KALA On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
London

kala pharmaceuticals inc (KALA) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
--
EPS TTM
--
Shares Outstanding
--
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for KALA PHARMACEUTICALS INC (KALA)
\

Related News

No related news articles were found.

kala pharmaceuticals inc (KALA) Related Businessweek News

No Related Businessweek News Found

kala pharmaceuticals inc (KALA) Details

Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles (MPP) technology for the treatment of eye diseases. The company’s lead product candidate is KPI-121 0.25% which has completed two Phase III clinical trials for the treatment of temporary relief of the signs and symptoms of dry eye disease; INVELTYS which has completed two Phase III clinical trials for the treatment of inflammation and pain following ocular surgery; and KPI-285, a MPP receptor tyrosine kinase inhibitor program, which is in preclinical studies for the treatment of retinal diseases. The company was formerly known as Hanes Newco, Inc. and changed its name to Kala Pharmaceuticals, Inc. in December 2009. Kala Pharmaceuticals, Inc. was founded in 2009 and is headquartered in Watertown, Massachusetts.

130 Employees
Last Reported Date: 03/12/19
Founded in 2009

kala pharmaceuticals inc (KALA) Top Compensated Officers

Chairman, President & CEO
Total Annual Compensation: $927.4K
Chief Operating Officer
Total Annual Compensation: $237.7K
Chief Medical Officer
Total Annual Compensation: $643.9K
General Counsel, Chief Compliance Officer & C...
Total Annual Compensation: $703.4K
Compensation as of Fiscal Year 2018.
kala pharmaceuticals inc
Kala Pharmaceuticals, Inc. Presents at Jefferies 2019 Healthcare Conference, Jun-06-2019 02:30 PM

Kala Pharmaceuticals, Inc. Presents at Jefferies 2019 Healthcare Conference, Jun-06-2019 02:30 PM. Venue: Grand Hyatt, 109 E 42nd St, New York, New York, United States. Speakers: Mark T. Iwicki, Chairman, President & CEO.

Kala Pharmaceuticals, Inc. Announces the Earnings Results for the First Quarter 2019

Kala Pharmaceuticals, Inc. announced the earnings results for the first quarter 2019. For the quarter the company reported loss from operations was $24.1 million compared to $11.1 million for the same period last year. Net loss was $25.4 million, or $0.75 per share as compared to a net loss of $11.3 million, or $0.46 per share a year ago.

Kala Pharmaceuticals, Inc. Presents at Bank of America Merrill Lynch 2019 Healthcare Conference, May-14-2019 08:15 AM

Kala Pharmaceuticals, Inc. Presents at Bank of America Merrill Lynch 2019 Healthcare Conference, May-14-2019 08:15 AM. Venue: Encore Hotel, Wynn, Las Vegas, Nevada, United States. Speakers: Mark T. Iwicki, Chairman, President & CEO.

 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

KALA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for KALA.
View Industry Companies
 

Industry Analysis

KALA

Industry Average

Valuation KALA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 124.9x
Price/Book 2.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact KALA PHARMACEUTICALS INC, please visit www.kalarx.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.